Revolution Medicines announces FDA BTD to elironrasib

Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to elironrasib, the company’s RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, NSCLC, who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor. The Breakthrough Therapy Designation is based on data from the Phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with advanced KRAS G12C solid tumors.